|
The Non-Hodgkin’s Lymphoma Drug Market Will Nearly Double to More Than …
Sacramento Bee The Pharmacor advisory service entitled Non-Hodgkin’s Lymphoma finds that sales of rituximab dominate the current market, and will continue to do so through 2022, regardless of biosimilar rituximab entry. Teva Pharmaceutical Industries’ … |
|
Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation
The Pharma Letter AbbVie’s partnership with Biogen Idec (Nasdaq: BIIB) on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that … |
|
Rituximab drug may be safe, effective for immunoglobulin G4-related disease …
News-Medical.net Rituximab (Rituxan®) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener’s), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called … |
|
Avacta looks set to reward an understanding of antibodies
Financial Times Affimer is the sort of word that gives Aim a bad name. Investors are unaccustomed to grappling with a dictionary when trying to understand a company’s business case. But Avacta, the animal health and biotechnology business, may be about to reward those … |
|
Common Rheumatoid Arthritis Treatment May Be Effective in Treating …
Science Daily (press release) Oct. 27, 2013 — Rituximab (Rituxan®) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener’s), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease … |
|
Common Rheumatoid Arthritis Treatment May Be Effective in Treating …
Newswise (press release) Newswise — SAN DIEGO – Rituximab (Rituxan®) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener’s), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related … |
|
Merus’ MeMo-derived common light chain antibodies receive European patent
pharmabiz.com Saturday, October 26, 2013, 16:00 Hrs [IST]. Merus BV, a biopharmaceutical company focusing on innovative antibody therapeutics, has received a European patent on its MeMo transgenic mouse for the generation of common light chain human antibodies. |
|
AbbVie Inc (ABBV): AbbVie’s CEO Discusses Q3 2013 Results – Earnings Call …
Seeking Alpha In addition to assets currently in late-stage such as HCV, daclizumab, elagolix, (inaudible) and elotuzumab were on the cusp of transitioning several additional programs in the Phase 3 development, including but not limited to ABT-199 per CLL and ABT … |
Jutia Group |
What’s Behind AbbVie’s Rocking Q3 Earnings
DailyFinance AbbVie’s partnership with Biogen Idec on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that study to wrap … AbbVie Inc (ABBV): AbbVie’s CEO Discusses Q3 2013 Results – Earnings Call …Seeking Alpha AbbVie Reports Third-Quarter 2013 Financial ResultsMarketWatch |
Infinity Pharmaceuticals Inc. (INFI): Infinity Pharmaceuticals Presents A …Seeking AlphaThis recommendation was based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free surv…